Drug Profile
Coluracetam
Alternative Names: BCI-540; MKC-231Latest Information Update: 24 Jul 2015
Price :
$50
*
At a glance
- Originator Mitsubishi Chemical
- Developer BrainCells; Mitsubishi Chemical; Takeda
- Class Neuroprotectants; Nootropics; Pyrrolidinones; Quinolines; Small molecules
- Mechanism of Action AMPA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Anxiety disorders; Major depressive disorder
Most Recent Events
- 26 Jun 2012 Coluracetam is available for licensing as of 26 Jun 2012. http://www.braincellsinc.com
- 15 May 2012 Mitsubishe Tanabe Pharma terminates a licence agreement for coluracetam (Mitsubishi Tanabe Pharma May 8 2012 pipeline)
- 16 Jun 2010 Safety and efficacy data from a phase IIa trial in Major depressive disorder with anxiety released by BrainCells